
    
      Each pSS patients (n=60) with Scores>=6 on ESSDAI received low-dose IL-2 or placebo (active
      group: placebo group =1:1, 1 million units every other day subcutaneously (HrIL-2 1X 106, ip,
      Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3 cycles. The
      end points were safety, clinical and immunologic response.
    
  